{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:13:11Z","timestamp":1761804791838,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofcardiologycases.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology Cases"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.jccase.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,10,13]],"date-time":"2013-10-13T04:15:10Z","timestamp":1381637710000},"page":"168-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic dilemmas in the treatment of acute coronary syndrome as manifestation of essential thrombocythaemia"],"prefix":"10.1016","volume":"8","author":[{"given":"Ivica","family":"Bo\u0161njak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Selthofer-Relati\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlatka","family":"Peri\u0161a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jccase.2013.08.001_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.jccase.2013.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra035363","article-title":"Thrombocytosis","volume":"350","author":"Schafer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"Gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jccase.2013.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jccase.2013.08.001_bib0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jccase.2013.08.001_bib0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jccase.2013.08.001_bib0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2008.004234","article-title":"Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study","volume":"94","author":"Girodon","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jccase.2013.08.001_bib0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0050","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factor for thrombosis, myelofibrosis and leukemia in essential thrombocytosis: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jccase.2013.08.001_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocytemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukaemia"},{"key":"10.1016\/j.jccase.2013.08.001_bib0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocytemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jccase.2013.08.001_bib0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2796.1998.00314.x","article-title":"Acute coronary disease in essential thrombocytemia and polycytemia vera","volume":"244","author":"Rossi","year":"1998","journal-title":"J Intern Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0070","first-page":"35","article-title":"Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera","volume":"36","author":"Tekin","year":"2008","journal-title":"Arch Turk Soc Cardiol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jccase.2013.08.001_bib0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/asheducation-2011.1.215","article-title":"Management of essential thrombocythemia","volume":"2011","author":"Cervantes","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jccase.2013.08.001_bib0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","article-title":"Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia","volume":"85","author":"De Stefano","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0090","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","article-title":"When and how to treat essential thrombocythemia","volume":"353","author":"Barbui","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0110","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states: experience in 577 patients","volume":"92","author":"Anagrelide Study Group","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0125","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jccase.2013.08.001_bib0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jccase.2013.08.001_bib0135","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: acturial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haemtol"},{"key":"10.1016\/j.jccase.2013.08.001_bib0140","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jccase.2013.08.001_bib0145","unstructured":"The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Acute myocardial infarction in patients presenting with ST-segment elevation (Management of). ESC Clinical Practice Guidelines. http:\/\/www.escardio.org\/GUIDELINES-SURVEYS\/ESC-GUIDELINES\/Pages\/acs-st-segment-elevation.aspx."}],"container-title":["Journal of Cardiology Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540913001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540913001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:08:12Z","timestamp":1761804492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878540913001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1878540913001096"],"URL":"https:\/\/doi.org\/10.1016\/j.jccase.2013.08.001","relation":{},"ISSN":["1878-5409"],"issn-type":[{"type":"print","value":"1878-5409"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic dilemmas in the treatment of acute coronary syndrome as manifestation of essential thrombocythaemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology Cases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jccase.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}